GB2167665A - Platelet aggregation inhibitor for use in polymeric surgical devices - Google Patents
Platelet aggregation inhibitor for use in polymeric surgical devices Download PDFInfo
- Publication number
- GB2167665A GB2167665A GB08430598A GB8430598A GB2167665A GB 2167665 A GB2167665 A GB 2167665A GB 08430598 A GB08430598 A GB 08430598A GB 8430598 A GB8430598 A GB 8430598A GB 2167665 A GB2167665 A GB 2167665A
- Authority
- GB
- United Kingdom
- Prior art keywords
- polymer
- platelet aggregation
- aggregation inhibitor
- pai
- size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 title claims abstract description 49
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 title claims abstract description 49
- 229940127218 antiplatelet drug Drugs 0.000 title claims abstract description 49
- 239000000106 platelet aggregation inhibitor Substances 0.000 title claims abstract description 49
- 229920000642 polymer Polymers 0.000 claims abstract description 39
- 210000001367 artery Anatomy 0.000 claims abstract description 6
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 22
- 239000000178 monomer Substances 0.000 claims description 7
- -1 polypropylene Polymers 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 3
- ZIDQIOZJEJFMOH-UHFFFAOYSA-N 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid Chemical group C1CCCCC1C(O)CCN1C(CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-UHFFFAOYSA-N 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 238000010640 amide synthesis reaction Methods 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 238000006266 etherification reaction Methods 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 abstract description 3
- 229940091173 hydantoin Drugs 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229910017333 Mo(CO)6 Inorganic materials 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- QFEOTYVTTQCYAZ-UHFFFAOYSA-N dimanganese decacarbonyl Chemical compound [Mn].[Mn].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] QFEOTYVTTQCYAZ-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
A polymeric surgical device such as a suture, ligating clip, catheter or artificial artery, has a platelet aggregation inhibitor, such as 5-(6-carboxyhexyl-1-(3-cyclohexyl-3-hydroxypropyl) hydantoin, associated therewith. The inhibitor may be coated onto the device or incorporated into the polymer.
Description
SPECIFICATION
Improvements in polymeric surgical devices
The present invention relates to improvements in polymeric surgical devices for use in blood vessels in the body, such as sutures, ligating clips, catheters, and internal prostheses.
Sutures and ligating clips are widely used in surgical procedures such as cardiac or vascular surgery, for instance to close off or connect together blood vessels or to connect internal prosthetic devices such as artificial arteries into an existing artery in place of an excised segment thereof.
Catheters are also often placed in blood vessels, for instance for monitoring blood pressure or composition or for extracting blood for analysis or renal dialysis.
However, the use of such devices in blood vessels may lead to the formation of blood clots around the device. For instance, it has been shown that in artificial arteries in the form of heat crimped, seamless, woven tubes of DACRON or TEFLON there is a tendency for blood clotting to take place on the internal surface of the tube in the region of the sutures if the tube's internal diameter is less than about 7mm.
According to the present invention a polymeric surgical device is provided having associated therewith a platelet aggregation inhibitor (PAI).
An example of a suitable PAI is the prostaglandin analogue 5-(6-ca rboxyhexyl)-l -(3-cyclohexyl-3- hydroxypropyl) hydantoin.
The polymeric device may be made from a natural or artificial polymer which may be absorbable or non-absorbable.
Suitable non-absorbable polymers are polypropylene, polyethylene, nylon or, for sutures, silk. Suitable absorbable polymers are polyglycolide, polylactide or polydioxanone.
The PAI may be associated with the polymeric device by, for instance,
(i) coating the device with a size containing the PAI,
(ii) chemically combining the PAI with the polymer, or
(iii) incorporating the PAI in the device during manufacture of the device.
In method (i) the PAI may simply be dissolved or mechanically dispersed in a size polymer solution. The solution is then applied to the device as a size. The size polymer may be, for instance, a styrene/maleic anhydride copolymer. In use, the PAI will diffuse out of the size polymer coating or matrix and so confer platelet aggregation inhibiting properties on the device.
The rate of such diffusion will depend on the molecular constitutions of the PAI and the size polymer matrix, and in some cases it may be undesirably high. In this event, the platelet aggregation inhibiting properties will be lost too rapidly. Thus it may be necessary to attach the PAI to the size polymer chain by chemical bonds. Such a platelet aggregation inhibiting polymer (PAIP) may be used as a component of the size for coating the device as described above. The reduced rate of diffusion of the PAI bonded to the bulky size polymer chain would ensure a longer period of platelet aggregation inhibiting activity of the device.
In method (ii), chemical attachment of the PAI to the polymer of the device represents the extreme degree of immobilisation of the PAI. This method ensures that the surface of the device presented to the blood stream is covered to a significant extent by bound PAI molecules.
The PAI may be attached to the polymer either "permanently", that is by chemical bonds which are not broken by the action of enzymes or other factors in blood, or "releasably", that is by chemical bonds which can be broken by the action of the enzymes or other factors in blood. In the first case, the platelet aggregation inhibiting activity is essentially a surface effect. In the second case there is a release of PAI from the surface and, more slowly, from the underlying layers of the device. The release of the PAI substantially inhibits thrombus formation on and in the neighbourhood of the device.
In method (iii) the PAI may be mechanically incorporated into the device either as itself or as a PAIP. For instance a polymer solution containing the PAI or a PAIP may be spun to produce a suture fibre or cast to produce a ligating clip or catheter. Preferably such spinning or casting is carried out at a temperature not significantly higher than ambient temperature.
A device according to the invention can only be produced by spinning or moulding a polymer melt containing the PAI or a PAIP if the PAI is thermally stable. However melt spinning or melt moulding may be used to form a device without any PAI therein. The PAI may then be incorporated in the device by immersing it in a solution containing a swelling agent and the PAI. This procedure is particularly suitable for producing nylon or polypropylene sutures and can be carried out before the final stretching process in suture fibre manufacture.
The details of the processes used in methods (i) and (ii) to chemically bond the PAI to the polymer or size polymer clearly depend on the chemical structures of the PAI and the polymer of which the device or the size is composed. If appropriate functional groups are present on the polymer and if complementary functional groups which can be used without impairing its activity are present on the PAI, any conventional linking type of reaction such as esterification, etherification or amide formation can be used.
Alternatively, a polymerisable double bond may be introduced into the PAI molecule. The modified PAI molecule may be copolymerised with a vinyl monomer to produce a PAIP. The modified PAI molecule or the
PAIP may be grafted into the polymer from which the device is made, or the PAIP may be used in method (i) or method (iii) above. For instance, the prostaglandin analogue 5-(6-carboxyhexyl)-l-(3-cyclohexyl-3- hydroxypropyl) hydantoin may be esterified with a vinyl monomer such as N-vinylpyrrolidone or, preferably, 2-hydroxyethylmethacrylate.
One particular method for grafting such a modified PAI onto a polymer embodying amide (or peptide) or urethane groups (for instance nylon, protein or polyurethane polymers) involves subjecting the polymer to a mild halogenation procedure, for instance using sodium hypochlorite or hypobromite. This treatment converts some of the -NHCO- or-NHCOO- groups into -NXCO- or-NXCOO- groups (wherein Xis chlorine or bromine).
The resulting halogenated polymer is dissolved in a vinyl polymer (M) and reacted with a free radical producing agent to produce free radicals-NCO- or-NCOO- orthe polymer. The free radical producing agent may be, for instance, a transition metal carbonyl such as Mo(CO)6, which is reacted thermally at about 60"C to form the free radicals, or Mn2 (CO)10, which is reacted photochemically at a wavelength of 436nm to form the free radicals.
Polymerisation of the free-radical containing polymer with the monomer M yields a graft copolymer containing structures such as
If the vinyl monomer M contains a proportion of modified PAI molecules, the grafted Mn chains will include units having the PAI molecule attached thereto.
It is envisaged that the present invention will be of particular, but not exclusive, application to surgical sutures for suturing blood vessels in cardiac and vascular surgery to substantially inhibit spontaneous thrombus formation.
It is also envisaged that any polymeric surgical device, in particular those for use in or adjacent blood vessels, can be provided with PAI according to the present invention. For instance, it is believed that the present invention is applicable to ligating clips, catheters and artificial arteries, as long as they are made of polymeric material.
One embodiment of a device according to the invention is now described by way of example only.
Two catheters of 2mm bore were prepared and placed in the main vein of a dog. The first was a polystyrene coated catheter; the second was coated with polystyrene in which 5-(6-carboxyhexyl)-1-(3cyclohexyl-3-hydroxypropyl) hydantoin had been dispersed. Both catheters remained in flowing blood for four hours and then each was withdrawn. The untreated catheter was found to be covered in thrombus material whereas that which was coated with the platelet aggregation inhibitor was not.
Claims (18)
1. A polymeric surgical device having associated therewith a platelet aggregation inhibitor.
2. The device of Claim 1 wherein the platelet aggregation inhibitor is 5-(6-carboxyhexyl)-1-(3-cyclohexyl- 3-hydroxypropyl) hydantoin.
3. The device of Claim 1 or Claim 2, which is made from a non-absorbable polymer.
4 The device of Claim 3, wherein the non-absorbable polymer is polypropylene, polyethylene, nylon or silk.
5. The device of Claim 1 or Claim 2, which is made from an absorbable polymer.
6. The device of Claim 5, wherein the absorbable polymer is polylactide, polyglycolide or polydioxanone.
7. The device of any one of Claims 1 to 6 in the form of a suture.
8. The device of any one of Claims 1 to 6 in the form of a ligating clip, catheter or artificial artery.
9. A method of producing a device according to any one of Claims 1 to 8, comprising coating the device with a size containing the platelet aggregation inhibitor.
10. The method of Claim 9, wherein the size contains a size polymer.
11. The method of Claim 10, wherein the platelet aggregation inhibitor is chemically bonded to the size polymer.
12. A method of producing a device according to any one of Claims 1 to 8, comprising chemically combining the platelet aggregation inhibitor with the polymer of which the device is composed.
13. A method of producing a device according to any one of Claims 1 to 8, comprising incorporating the platelet aggregation inhibitor in the polymer of which the device is composed.
14. The method of Claim 13, wherein the device is spun or cast from a solution containing the platelet aggregation inhibitor.
15. The method of Claim 14, wherein the solution contains a polymer to which the platelet aggregation inhibitor is chemically bonded.
16. The method of Claim 13, wherein the device is immersed in a solution containing a swelling agent and the platelet aggregation inhibitor.
17. The method of any one of Claims 11, 12 and 15, wherein the platelet aggregation inhibitor is chemically bonded to the polymer by esterification, etherification or amide formation.
18. The method of any one of Claims 11, 12 and 15, wherein the polymer contains amide or urethane groups, the platelet aggregation inhibitor is attached to a monomer containing a polymerisable double bond, a free radical is produced on a plurality of the amide or urethane groups, and the inhibitor containing monomer, optionally in admixture with unmodified monomer, is free-radical graft polymerised onto the polymer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08430598A GB2167665A (en) | 1984-12-04 | 1984-12-04 | Platelet aggregation inhibitor for use in polymeric surgical devices |
| DE19853542703 DE3542703A1 (en) | 1984-12-04 | 1985-12-03 | SURGICAL DEVICE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08430598A GB2167665A (en) | 1984-12-04 | 1984-12-04 | Platelet aggregation inhibitor for use in polymeric surgical devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8430598D0 GB8430598D0 (en) | 1985-01-09 |
| GB2167665A true GB2167665A (en) | 1986-06-04 |
Family
ID=10570681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08430598A Withdrawn GB2167665A (en) | 1984-12-04 | 1984-12-04 | Platelet aggregation inhibitor for use in polymeric surgical devices |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE3542703A1 (en) |
| GB (1) | GB2167665A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308802A3 (en) * | 1987-09-18 | 1990-04-11 | Olav Prof. Dr. Thulesius | Composition for preventing and treating thrombosis, and hemocompatible surgical implant therefor |
| US5182317A (en) * | 1988-06-08 | 1993-01-26 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
| US5262451A (en) * | 1988-06-08 | 1993-11-16 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
| US5338770A (en) * | 1988-06-08 | 1994-08-16 | Cardiopulmonics, Inc. | Gas permeable thrombo-resistant coatings and methods of manufacture |
| US5342693A (en) * | 1988-06-08 | 1994-08-30 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coating and methods of manufacture |
| WO1997005193A1 (en) * | 1995-07-28 | 1997-02-13 | Sanitaria Scaligera Spa | A process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated |
| US6107453A (en) * | 1995-07-28 | 2000-08-22 | Sanitaria Scaligera S.P.A. | Process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated |
| WO2001017578A1 (en) * | 1999-09-03 | 2001-03-15 | J. Uriach & Cia S.A. | New biocompatible polymer systems carrying triflusal or htb |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1205770A (en) * | 1966-07-26 | 1970-09-16 | Nat Patent Dev Corp | Body implants |
| GB1602163A (en) * | 1977-03-22 | 1981-11-11 | Snam Progetti | Bio compatible articles |
-
1984
- 1984-12-04 GB GB08430598A patent/GB2167665A/en not_active Withdrawn
-
1985
- 1985-12-03 DE DE19853542703 patent/DE3542703A1/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1205770A (en) * | 1966-07-26 | 1970-09-16 | Nat Patent Dev Corp | Body implants |
| GB1602163A (en) * | 1977-03-22 | 1981-11-11 | Snam Progetti | Bio compatible articles |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308802A3 (en) * | 1987-09-18 | 1990-04-11 | Olav Prof. Dr. Thulesius | Composition for preventing and treating thrombosis, and hemocompatible surgical implant therefor |
| US5182317A (en) * | 1988-06-08 | 1993-01-26 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
| US5262451A (en) * | 1988-06-08 | 1993-11-16 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
| US5338770A (en) * | 1988-06-08 | 1994-08-16 | Cardiopulmonics, Inc. | Gas permeable thrombo-resistant coatings and methods of manufacture |
| US5342693A (en) * | 1988-06-08 | 1994-08-30 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coating and methods of manufacture |
| WO1997005193A1 (en) * | 1995-07-28 | 1997-02-13 | Sanitaria Scaligera Spa | A process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated |
| US6107453A (en) * | 1995-07-28 | 2000-08-22 | Sanitaria Scaligera S.P.A. | Process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated |
| WO2001017578A1 (en) * | 1999-09-03 | 2001-03-15 | J. Uriach & Cia S.A. | New biocompatible polymer systems carrying triflusal or htb |
| ES2154242A1 (en) * | 1999-09-03 | 2001-03-16 | Uriach & Cia Sa J | New biocompatible polymer systems carrying triflusal or htb |
| US6979465B1 (en) | 1999-09-03 | 2005-12-27 | J. Uriach & Cia, S.A. | Biocompatible polymer systems carrying triflusal or HTB |
| US7445789B2 (en) | 1999-09-03 | 2008-11-04 | Palau Pharma, S.A. | Biocompatible polymeric systems carrying triflusal or HTB |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8430598D0 (en) | 1985-01-09 |
| DE3542703A1 (en) | 1986-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5004461A (en) | Methods for rendering plastics thromboresistant and product | |
| US5298255A (en) | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material | |
| US7303575B2 (en) | Embolism protection devices | |
| Yoneyama et al. | Short‐term in vivo evaluation of small‐diameter vascular prosthesis composed of segmented poly (etherurethane)/2‐methacryloyloxyethyl phosphorylcholine polymer blend | |
| WO1992017218A1 (en) | Composite artificial blood vessel | |
| JP2004534579A (en) | Polysaccharide biomaterial and use thereof | |
| EP0366564A2 (en) | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material | |
| JPH04202441A (en) | Medical tool having surface lubricity when wet and preparation thereof | |
| GB2167665A (en) | Platelet aggregation inhibitor for use in polymeric surgical devices | |
| JPH07184989A (en) | Hemocompatible medical polymeric materials and medical materials | |
| Watanabe | Microarterial prostheses of expanded polytetrafluoroethylene | |
| JPS61263448A (en) | Blood vessel prosthesis | |
| CN114588308B (en) | High-strength and easily-sutured non-absorbable medical suture line and preparation method thereof | |
| JPH05269196A (en) | Multilayered artificial blood vessel | |
| Eberhart et al. | Cardiovascular materials | |
| JPH04288165A (en) | Organ implant and manufacture thereof | |
| JPS60190966A (en) | Anti-thrombotic material | |
| Leung et al. | Biodegradable, thermosensitive implant for approximating cylindrical structures: A preliminary study | |
| Kennedy | Novel designed polyisobutylene-based biopolymers: synthesis, characterization, and biological testing of amphiphilic chameleon networks | |
| JPS6320552B2 (en) | ||
| CN120605373B (en) | Self-healing and wearable artificial blood vessel and its application | |
| JPS62152468A (en) | Composite structure tubular organ prosthesis | |
| JPS62240066A (en) | Medical tubular organ and its production | |
| Terada et al. | Experimental study of ectopic‐free tissue transfer of rabbit epigastric flap using small‐caliber vascular grafts | |
| RU2405002C1 (en) | Method of producing thromboresistant polymer materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |